RU2340618C2 - Диазинопиримидины и фармацевтическая композиция, содержащая их - Google Patents
Диазинопиримидины и фармацевтическая композиция, содержащая их Download PDFInfo
- Publication number
- RU2340618C2 RU2340618C2 RU2005119281/04A RU2005119281A RU2340618C2 RU 2340618 C2 RU2340618 C2 RU 2340618C2 RU 2005119281/04 A RU2005119281/04 A RU 2005119281/04A RU 2005119281 A RU2005119281 A RU 2005119281A RU 2340618 C2 RU2340618 C2 RU 2340618C2
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- compound according
- halogen
- oxygen
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 239000001301 oxygen Substances 0.000 claims abstract 7
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims abstract 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract 3
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims abstract 3
- 125000002252 acyl group Chemical group 0.000 claims abstract 3
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 3
- 150000002367 halogens Chemical class 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims abstract 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims abstract 2
- 108091008794 FGF receptors Proteins 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- -1 cyano, hydroxyl Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- KLVQAIJZDCCJRZ-UHFFFAOYSA-N 2h-1,3,4-thiadiazine Chemical compound C1SC=CN=N1 KLVQAIJZDCCJRZ-UHFFFAOYSA-N 0.000 claims 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 claims 1
- DRUDUUISAAIUKM-UHFFFAOYSA-N 7-methylsulfanyl-1,3-diphenylpyrimido[4,5-e][1,3,4]thiadiazine Chemical compound C12=NC(SC)=NC=C2SC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 DRUDUUISAAIUKM-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Изобретение относится к новым химическим соединениям формулы (I) или его фармацевтически приемлемым солям, которые обладают ингибирующим действием в отношении киназы р-38 MAP и киназы FGFR, и могут быть использованы при лечении таких заболеваний, как артрит, обструктивное заболевание легких, болезнь Альцгеймера или онкологических и др. заболеваний. В общей формуле (I)
R1 означает водород, R2 означает 6-членный кислородсодержащий гетероциклил, арил, выбранный из незамещенного фенила или фенила, замещенного алифатической ацильной группой, содержащей 1-6 атомов углерода, галогеном, циано, гидроксилом, С1-6алкилсульфинилом,С1-6 алкилсульфонилокси, C1-6алкилсульфонилом, С1-6алкилсульфанилом, трет.бутидиметилсиланилокси, 6-членным гетероциклилом, содержащим 1-2-гетероатома, выбранных из азота и кислорода, R3 означает C1-6алкил, Ar1 означает фенил, замещенный 1-2 заместителями, выбранными из атомов галогена, C1-6алкила, C1-6алкокси, амино, C1-6алкиламино, ди(С1-6алкил)амино, Х1 означает кислород и X2 означает химическую связь. Изобретение также относится к фармацевтической композиции с использованием соединений изобретения. 3 н. и 10 з.п. ф-лы, 1 табл., 64 пр.
Description
Claims (13)
1. Соединение формулы
или его фармацевтически приемлемая соль, где
R1 означает водород,
R2 означает 6-членный кислородсодержащий гетероциклил, арил, выбранный из незамещенного фенила или фенила, замещенного алифатической ацильной группой, содержащей 1-6 атомов углерода, галогеном, циано, гидроксилом,
С1-6алкилсульфинилом, С1-6алкилсульфонилокси, С1-6алкилсульфонилом, С1-6алкилсульфанилом, трет.бутилдиметилсиланилокси, 6-членным гетероциклилом, содержащим 1-2-гетероатома, выбранных из азота и кислорода,
R3 означает C1-6алкил,
Ar1 означает фенил, замещенный 1-2 заместителями, выбранными из атомов галогена,
C1-6алкила, C1-6алкокси, амино, C1-6алкиламино, ди(С1-6алкил)амино,
X1 означает кислород и
Х2 означает химическую связь.
2. Соединение по п.1, где R2 означает незамещенный фенил или фенил, замещенный алифатической ацильной группой, содержащей 1-6 атомов углерода, галогеном, циано, гидроксилом, С1-6алкилсульфинилом,С1-6алкилсульфонилокси, C1-6алкилсульфонилом, С1-6алкилсульфанилом, трет.бутилдиметилсиланилокси, 6-членным гетероциклилом, содержащим 1-2-гетероатома, выбранных из азота и кислорода,
3. Соединение по п.1, где R2 означает гетероциклилфенил, C1-С6алкилсульфинилфенил, C1-С6алкилсульфонилфенил, фенил, галогенфенил, гидроксифенил, C1-С6 ацилфенил, цианофенил, C1-С6алкилсульфонилоксифенил.
4. Соединение по п.1, где R2 означает гетероциклилфенил,
C1-С6алкилсульфинилфенил, C1-С6алкилсульфонилфенил, фенил или галогенфенил.
5. Соединение по п.1, где Ar1 означает 2-галогенфенил, 4-галогенфенил, 2,4-дигалогенфенил, 2,6-дигалогенфенил, 2-С1-С6алкилфенил, 1-C1-С6алкоксифенил, 2-C1-С6алкоксифенил, 4-С1-С6алкоксифенил, 3,5-ди-С1-С6алкоксифенил, 2-галоген-5-C1-С6алкоксифенил или 2-ди-С1-С6алкиламино-6-фторфенил.
6. Соединение по п.3 где R3 означает метил.
7. Соединение по п.6, где R2 означает 4-(морфолин-4-ил)фенил.
8. Соединение по п.7, где Ar1 означает 2-бромфенил.
9. Соединение по п.7, где Ar1 означает 2,6-дихлорфенил.
10. Соединение по п.6, где R2 означает 3-метилсульфинилфенил.
11. Соединение по п.10, где Ar1 означает 2-бромфенил.
12. Фармацевтическая композиция, обладающая ингибирующим действием в отношении киназы р-38 MAP и киназы FGFR, включающая
(а) соединение по любому из пп.1-5 в эффективном количестве, и
(б) фармацевтически приемлемый эксципиент.
13. Соединение формулы
где n равно 0, 1 или 2,
R7 означает C1-6алкил,
R3, Ar1, Х1, Х2 имеют значения, указанные в п.1;
при условии, что исключены следующие соединения: 7-метилсульфанил-1,3-дифенил-1Н-пиримидо[4,5-е][1,3,4]тиадиазин, 7-метансульфанил-3-фенил-1Н-пиримидо[4,5-е][1,3,4]тиадиазин и 7-метилсульфанил-1,3-дифенил-1Н-пиримидо[4,5-е][1,3,4]оксадиазин.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42765202P | 2002-11-18 | 2002-11-18 | |
US60/427,652 | 2002-11-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005119281A RU2005119281A (ru) | 2006-03-20 |
RU2340618C2 true RU2340618C2 (ru) | 2008-12-10 |
Family
ID=32326577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005119281/04A RU2340618C2 (ru) | 2002-11-18 | 2003-11-12 | Диазинопиримидины и фармацевтическая композиция, содержащая их |
Country Status (14)
Country | Link |
---|---|
US (2) | US6943158B2 (ru) |
EP (1) | EP1565475B1 (ru) |
JP (1) | JP2006514624A (ru) |
KR (1) | KR20050075028A (ru) |
CN (1) | CN100357293C (ru) |
AT (1) | ATE427951T1 (ru) |
AU (1) | AU2003283393A1 (ru) |
BR (1) | BR0316375A (ru) |
CA (1) | CA2506565A1 (ru) |
DE (1) | DE60327097D1 (ru) |
MX (1) | MXPA05005028A (ru) |
PL (1) | PL377620A1 (ru) |
RU (1) | RU2340618C2 (ru) |
WO (1) | WO2004046152A1 (ru) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
NZ566180A (en) | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
US20090192164A1 (en) * | 2006-06-28 | 2009-07-30 | Aska Pharmaceutical Co., Ltd. | Treating agent of inflammatory bowel disease |
EP1918284A1 (en) * | 2006-10-30 | 2008-05-07 | Glaxo Group | Hydrazinopyrimidines as cysteine protease inhibitors |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
RU2520098C2 (ru) | 2008-06-26 | 2014-06-20 | Ресверлоджикс Корп. | Способы получения производных хиназолинона |
DE102008063561A1 (de) * | 2008-12-18 | 2010-08-19 | Bayer Cropscience Ag | Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide |
AU2010204106B2 (en) | 2009-01-08 | 2014-05-08 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
KR20180096823A (ko) | 2009-04-22 | 2018-08-29 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
RS58911B1 (sr) | 2011-11-01 | 2019-08-30 | Resverlogix Corp | Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP3822273B1 (en) | 2012-06-13 | 2024-04-10 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | ブロモドメイン阻害剤としての新規複素環式化合物 |
SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
CN103757026B (zh) | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
MX2017010673A (es) | 2015-02-20 | 2018-03-21 | Incyte Corp | Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr). |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN112566912A (zh) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Fgfr抑制剂的盐 |
CN112867716A (zh) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
AU2020366006A1 (en) | 2019-10-14 | 2022-04-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1353534A (en) | 1971-07-13 | 1974-05-22 | Roche Products Ltd | Pyrimidotriazines and a process for the manufacture thereof |
US4025510A (en) * | 1975-12-01 | 1977-05-24 | E. I. Du Pont De Nemours And Company | 2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines |
BR0015243A (pt) * | 1999-10-21 | 2002-07-16 | Hoffmann La Roche | Heterociclos de nitrogênio bicìclico substituìdos por heteroalquilamino como inibidores da proteìna cinase p38 |
CA2420286A1 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
US6642381B2 (en) * | 2001-12-27 | 2003-11-04 | Hoffman-La Roche Inc. | Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors |
-
2003
- 2003-11-12 DE DE60327097T patent/DE60327097D1/de not_active Expired - Fee Related
- 2003-11-12 BR BR0316375-0A patent/BR0316375A/pt not_active IP Right Cessation
- 2003-11-12 JP JP2004552580A patent/JP2006514624A/ja active Pending
- 2003-11-12 RU RU2005119281/04A patent/RU2340618C2/ru not_active IP Right Cessation
- 2003-11-12 KR KR1020057008919A patent/KR20050075028A/ko not_active Application Discontinuation
- 2003-11-12 CN CNB2003801035760A patent/CN100357293C/zh not_active Expired - Fee Related
- 2003-11-12 AU AU2003283393A patent/AU2003283393A1/en not_active Abandoned
- 2003-11-12 MX MXPA05005028A patent/MXPA05005028A/es active IP Right Grant
- 2003-11-12 PL PL377620A patent/PL377620A1/pl not_active Application Discontinuation
- 2003-11-12 AT AT03775346T patent/ATE427951T1/de not_active IP Right Cessation
- 2003-11-12 WO PCT/EP2003/012652 patent/WO2004046152A1/en active Application Filing
- 2003-11-12 EP EP03775346A patent/EP1565475B1/en not_active Expired - Lifetime
- 2003-11-12 CA CA002506565A patent/CA2506565A1/en not_active Abandoned
- 2003-11-18 US US10/715,666 patent/US6943158B2/en not_active Expired - Fee Related
-
2005
- 2005-07-27 US US11/190,292 patent/US20050261284A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
ELLIOTT A.J. et al. "Reactions of benzothiohydrazide as bidentatate nucleochile", J.of Heterocyclic Chemistry, v.l8, no.6, 1981, s.799-800 (example 8). ELLIOTT A.J. et al. "Hydrazides and Thiohydrazides as Sources of Condensed Oxadiazines and Thiadiazines, Including Novel Azo Derivatives Bazed on Dithizone" J. of Heterocyclic Chemistry, v.45, no.l8, 1980, s.3677-3681. * |
Also Published As
Publication number | Publication date |
---|---|
CN1714093A (zh) | 2005-12-28 |
WO2004046152A1 (en) | 2004-06-03 |
JP2006514624A (ja) | 2006-05-11 |
US6943158B2 (en) | 2005-09-13 |
MXPA05005028A (es) | 2005-08-03 |
RU2005119281A (ru) | 2006-03-20 |
KR20050075028A (ko) | 2005-07-19 |
US20040097493A1 (en) | 2004-05-20 |
PL377620A1 (pl) | 2006-02-06 |
ATE427951T1 (de) | 2009-04-15 |
US20050261284A1 (en) | 2005-11-24 |
DE60327097D1 (de) | 2009-05-20 |
EP1565475B1 (en) | 2009-04-08 |
AU2003283393A1 (en) | 2004-06-15 |
CA2506565A1 (en) | 2004-06-03 |
EP1565475A1 (en) | 2005-08-24 |
CN100357293C (zh) | 2007-12-26 |
BR0316375A (pt) | 2005-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2340618C2 (ru) | Диазинопиримидины и фармацевтическая композиция, содержащая их | |
RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
RU2363700C2 (ru) | Производные хинуклидина и фармацевтические композиции, содержащие их | |
RS28004A (en) | Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease | |
EA200400073A1 (ru) | Пирролопиримидины как ингибиторы протеинкиназы | |
EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
CY1111093T1 (el) | 2,4,δι(ετερο-)αρυλαμινο(-οξυ)-5-υποκατεστημενες πυριμιδινες ως μεσα κατα των νεοπλασιων | |
RU2354655C2 (ru) | Ингибиторы сомт | |
ATE258552T1 (de) | Oxazolidinon-derivate als antibiotika, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen | |
TR200100300T2 (tr) | Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri | |
EA200500376A1 (ru) | Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf) | |
UY28211A1 (es) | Compuestos de hidroximetilo | |
EA200600928A1 (ru) | Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами | |
EA200400606A1 (ru) | ИНГИБИТОРЫ ФАКТОРА Ха И ДРУГИХ СЕРИНОВЫХ ПРОТЕАЗ, ВОВЛЕЧЁННЫХ В КОАГУЛЯЦИОННЫЙ КАСКАД | |
ATE334973T1 (de) | Chinazolinverbindungen | |
RU2005105337A (ru) | Противомикробные хинолины, их композиции и применение | |
EA200600225A1 (ru) | Производные пиперазина для лечения вич инфекций | |
DE602005022764D1 (de) | Piperidin- und azetidinderivate als glyt1-inhibitoren | |
HUP0100388A2 (hu) | Készítmények és eljárások csontritkulás kezelésére és a koleszterinszint csökkentésére | |
NO301543B1 (no) | 2-£4-(kinazolinylmetylamino)benzamido|-4-(tetrazolyl)smörsyrederivater med anti-tumor-aktivitet | |
EA200400086A1 (ru) | Новые производные оксазолидинонов в качестве антибактериальных агентов | |
EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение | |
RU2460723C2 (ru) | Производные 4-(1-аминоэтил)циклогексиламина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20091113 |